• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Learn Why The Bull Case For Vera Therapeutics Stock Could Change Following Wider Net Losses

    Simply Wall St·11/14/2026 23:21:05
    Listen to the news
    • Vera Therapeutics reported third quarter 2026 results, with a net loss of US$93.71 million and basic loss per share of US$1.30, and for the nine months to September reported a net loss of US$324.22 million and basic loss per share of US$4.51.
    • The widening loss profile highlights the cash demands of building a nephrology focused commercial platform and advancing BAFF/APRIL programs before TRUTAKNA and pipeline assets can offset research, development and selling expenses.
    • The next step is to consider how Vera Therapeutics' investment narrative incorporates this larger reported net loss and what implications that may have.

    Scan other nephrology and healthcare developers facing similar cash burn and late stage trial costs with our hand picked 36 healthcare AI stocks list, which keeps the focus on high potential therapeutics platforms.

    Vera Therapeutics Investment Narrative Recap

    To own Vera Therapeutics, you need to believe the TRUTAKNA franchise and BAFF/APRIL pipeline can eventually outrun the current cash burn. The analyst consensus narrative on Simply Wall St leans on that view, with expectations of high revenue and earnings growth over time. The latest quarterly loss reinforces how dependent the story is on scaling prescriptions and controlling operating spend.

    The short term catalyst still centers on execution in IgA nephropathy, from physician adoption to payer support, rather than this single earnings release. The biggest risk is that expenses tied to the nephrology sales force and research remain high while TRUTAKNA uptake or new indications do not build quickly enough to narrow those losses.

    The most relevant development here is the third quarter and year to date 2026 earnings update, which provides a clearer view of how much it currently costs Vera Therapeutics to run late stage programs and a commercial build out. A net loss of US$93.71 million for the quarter and US$324.22 million for nine months shows the scale of funding the business is consuming.

    For shareholders, that report feeds directly into questions about cash runway, potential future capital raises and how tightly management can manage spending while advancing TRUTAKNA and the broader BAFF/APRIL portfolio. It sits alongside the existing catalysts around IgA nephropathy data, patient pool size and commercialization progress, and keeps operational execution risk in clear focus.

    Vera Therapeutics' analyst narrative points to forecast revenue of US$900.1 million and earnings of US$137.4 million by 2029, based on an assumed yearly revenue expansion of 344.1% and an earnings swing of about US$552.7 million from current earnings of a US$415.3 million loss.

    Explore how Vera Therapeutics' fair value points to a 156% potential upside from its current price before the market closes the gap.

    NasdaqGM:VERA 1-Year Stock Price Chart
    NasdaqGM:VERA 1-Year Stock Price Chart

    Exploring Other Perspectives

    Some of the most optimistic analysts frame the key catalyst very differently for Vera Therapeutics. They focus on TRUTAKNA’s potential label expansion using the full ORIGIN 3 eGFR data, backing forecasts of about US$1.3b in revenue and US$397.6 million in earnings by 2029. Those projections were set before this latest loss, and views may evolve.

    Explore 2 other Vera Therapeutics fair value estimates, including one that suggests up to 1205% upside from the current price!

    Decide For Yourself

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    • A great starting point for your Vera Therapeutics research is our analysis highlighting 2 key rewards that could impact your investment decision.
    • See our latest analysis for Vera Therapeutics. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Vera Therapeutics' overall financial health at a glance.

    Looking for more investment ideas beyond Vera Therapeutics?

    Once you have formed a view on Vera Therapeutics, it can help to compare that thesis with other opportunities that share similar qualities or offer a different balance of risk and potential reward.